Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Synthetic Lethality Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PARP2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PARP2 Full-Length & Catalytic Domain Recombinant Protein (WT & Mutant Panel). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Theoretical MW confirmed. | View PARP2 Products |
| Gene Delivery | PARP2 Promise-ORF / Lentivirus. Full-length ORF for stable cell line construction in BRCA-deficient backgrounds. | View PARP2 Products |
| Benchmark Ab | Anti-PARP2 Recombinant Monoclonal (Catalytic Domain Specific). Research-grade positive control for binding and IP validation. | View PARP2 Products |
| Validator | PARP2 siRNA Set. For knockdown verification and specificity controls in cellular PARylation assays. | View PARP2 Products |
| Related Target | PARP1. Close homolog for selectivity counter-screening and PARP-trapping comparison. | View PARP1 Products |
| Related Target | PARP3. Off-target profiling member of the PARP superfamily. | View PARP3 Products |
| Related Target | BRCA1. Synthetic lethality pathway partner for combination strategy validation. | View BRCA1 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| PARP1/3 Selectivity & Off-Target Profiling | Human PARP1, PARP2, and PARP3 Catalytic Domains available with >95% purity and Sequence-Verified identity. HEK293-expressed where glycosylation state matters. |
| Drug Resistance Mutation Analysis | PARP2 Mutant Recombinant Protein Panel covering Catalytic and DNA-Binding domains. High-purity (>95%) proteins for SPR/BLI affinity and IC50 shift detection. |
| PARP Trapping & Cellular Mechanism Studies | Full-Length PARP2 Lentivirus and ORF reagents for stable cell line engineering. Endotoxin-controlled, suitable for synthetic lethality and trapping assays. |
| Assay Specificity & False Positive Control | Validated PARP2 siRNA Set included for knockdown confirmation in cellular target engagement studies. |
PARP2 Protein Structure & Key Mutations
PARP2 (UniProt Q9UGN5) contains three functional domains: the WGR domain, the PARP alpha-helical domain, and the PARP catalytic domain. The catalytic domain is responsible for poly(ADP-ribose) polymerase activity, while the WGR domain mediates DNA-dependent activation. Clinically relevant mutations found in dbSNP include rs3093905, rs3093906, and rs3093921, which may impact drug binding and contribute to acquired resistance. TarMart offers recombinant mutant protein panels covering these hotspots to support mechanism-of-resistance studies.
Live PARP2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PARP-targeted therapeutics is intensifying. First-generation dual PARP1/2 inhibitors (olaparib, niraparib, rucaparib, talazoparib) have demonstrated clinical benefit in ovarian, breast, prostate, and pancreatic cancers, but their dose-limiting hematologic and neurologic toxicities are largely attributed to PARP1 trapping and PARP2 inhibition. This has driven a paradigm shift: next-generation programs pursue either PARP2-selective inhibition (to spare PARP1-related toxicities while retaining synthetic lethality in BRCA-deficient tumors) or ultra-selective PARP1 inhibition (where PARP2 becomes an anti-target requiring strict avoidance). Emerging modalities include PROTAC degraders for refractory tumors and rational combinations with ATR inhibitors, WEE1 inhibitors, or immune checkpoint blockers. The field is also exploring CNS-penetrant variants for metastatic disease and tissue-specific prodrug strategies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PARP1/2 Dual) | AstraZeneca, GSK, Pfizer, Clovis Oncology | Ovarian, Breast, Prostate, Pancreatic Cancers | Selectivity Assay: need purified PARP1/2/3 catalytic domains for IC50 profiling. |
| Small Molecule (PARP2-Selective) | Emerging Biotech & Pharma Pipelines | Solid Tumors, Potential CNS Metastases | Homolog & Mutant Panel: need PARP2 WT/Mut vs PARP1 WT for selectivity window. |
| PROTAC / Targeted Degrader | Kymera, Arvinas, C4 Therapeutics (Preclinical) | PARPi-Refractory Tumors | Full-Length Protein & E3 Ligase Reagents: need PARP2-E3 binary/ternary complex formation assays. |